FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients, Pennsylvania, Spring House Beloud

@wfmz.com · 1 hour

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

The U.S. Food and Drug Administration has officially approved Johnson & Johnson's IMAAVY (nipocalimab-aahu) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA). This lan...

Read more Wfmz.com